Recombinate is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia A. Recombinate can also be used for perioperative (before, during, and after surgery) care. The technical name of Recombinate is Antihemophilic factor (recombinant).
Recombinate is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Recombinate is given as an intravenous injection.
Recombinate comes as a powder that must be reconstituted before injection.
The FDA-approved label for Recombinate lists common side effects including chills, rash, flushed skin, and nosebleeds.
Rare but serious side effects listed for Recombinate include life-threatening hypersensitivity reactions and the development of inhibitors.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America